Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

The role of peptidyl-prolyl isomerase Pin1 on androgen receptor activity in prostate cancer

FY 2013-14

Summary
Prostate cancer is the most common type of cancer for men in Canada. Current treatments for prostate cancer focus on stopping the production of testosterone that makes the tumour grow, either by using drugs to stop the body from producing it or by removing the testes where it is made. This may be initially successful, but for 90% of patients, the cancer develops to grow without testosterone and advances into a more aggressive castration-resistant prostate cancer. We have no cure for this type of advanced prostate cancer and the life expectancy is only about two years. In order to survive, healthy prostate cells depend on the androgen receptor, a protein that recruits cellular machinery to express genetic information when it recognizes testosterone. How the androgen receptor behaves in cancer cells when testosterone is removed remains a mystery. Besides testosterone, the androgen receptor is also affected by other growth factors, such as when there is local inflammation. It is believed that certain growth factors can turn on a series of chemical reactions that modify the behaviour of the androgen receptor. Other studies have shown that activation of the androgen receptor by growth factors involves phosphorylation, which is the process of adding a phosphate group to a protein to modify its behaviour. Current drug treatments for prostate cancer overlook this problem, and instead only focus on preventing the androgen receptor from recognizing testosterone. Our research team has recently discovered a compound from a marine sponge, EPI-001, which can stop the androgen receptor from responding to testosterone and potentially growth factors as well. EPI-001 can cause tumours to shrink without apparent toxic effects in laboratory mice, but we need to learn more about how it works. We found that EPI-001 binds to a spot on the androgen receptor that prevents it from interacting with the cellular machinery necessary to start reading genetic information. In our project, we hypothesize that EPI-002, the most potent form of EPI-001, can prevent the androgen receptor from cooperating with Pin1, a protein that can affect the shape of other proteins when they have been modified by phosphorylation. Pin1 was found in higher amounts from tumour samples of patients who later developed castration-resistant prostate cancer. A high amount of Pin1 can be found in other types of cancer as well and this may be a contributing factor to the development of cancer in general. Our plan is to better our understanding of the relationship between Pin1 and the androgen receptor and how this can have an effect on prostate cancer. We have the exciting opportunity to test the effectiveness of EPI-002, to understand how EPI-002 affects the androgen receptor, so that we may improve the design of new drugs that can be used to delay or cure prostate cancer.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
311937
Name
Leung Jacky
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The role of peptidyl-prolyl isomerase Pin1 on androgen receptor activity in prostate cancer
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Androgen Receptor; Drug Development; Hormone Dependent Cancer; Post-Phoshorylation Regulation; Prostate Cancer
Abstract
Prostate cancer is the most common type of cancer for men in Canada. Current treatments for prostate cancer focus on stopping the production of testosterone that makes the tumour grow, either by using drugs to stop the body from producing it or by removing the testes where it is made. This may be initially successful, but for 90% of patients, the cancer develops to grow without testosterone and advances into a more aggressive castration-resistant prostate cancer. We have no cure for this type of advanced prostate cancer and the life expectancy is only about two years. In order to survive, healthy prostate cells depend on the androgen receptor, a protein that recruits cellular machinery to express genetic information when it recognizes testosterone. How the androgen receptor behaves in cancer cells when testosterone is removed remains a mystery. Besides testosterone, the androgen receptor is also affected by other growth factors, such as when there is local inflammation. It is believed that certain growth factors can turn on a series of chemical reactions that modify the behaviour of the androgen receptor. Other studies have shown that activation of the androgen receptor by growth factors involves phosphorylation, which is the process of adding a phosphate group to a protein to modify its behaviour. Current drug treatments for prostate cancer overlook this problem, and instead only focus on preventing the androgen receptor from recognizing testosterone. Our research team has recently discovered a compound from a marine sponge, EPI-001, which can stop the androgen receptor from responding to testosterone and potentially growth factors as well. EPI-001 can cause tumours to shrink without apparent toxic effects in laboratory mice, but we need to learn more about how it works. We found that EPI-001 binds to a spot on the androgen receptor that prevents it from interacting with the cellular machinery necessary to start reading genetic information. In our project, we hypothesize that EPI-002, the most potent form of EPI-001, can prevent the androgen receptor from cooperating with Pin1, a protein that can affect the shape of other proteins when they have been modified by phosphorylation. Pin1 was found in higher amounts from tumour samples of patients who later developed castration-resistant prostate cancer. A high amount of Pin1 can be found in other types of cancer as well and this may be a contributing factor to the development of cancer in general. Our plan is to better our understanding of the relationship between Pin1 and the androgen receptor and how this can have an effect on prostate cancer. We have the exciting opportunity to test the effectiveness of EPI-002, to understand how EPI-002 affects the androgen receptor, so that we may improve the design of new drugs that can be used to delay or cure prostate cancer.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Leung, Jacky
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~